MARKET

CBLI

CBLI

Cleveland Biolbs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.110
+0.100
+3.32%
After Hours: 3.110 0 0.00% 16:32 11/25 EST
OPEN
3.000
PREV CLOSE
3.010
HIGH
3.180
LOW
2.950
VOLUME
92.01K
TURNOVER
--
52 WEEK HIGH
5.43
52 WEEK LOW
0.5000
MARKET CAP
40.48M
P/E (TTM)
-15.3429
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DBV Technologies, AnPac Bio-Medical Science leads healthcare gainers; Liquidia Technologies, Jounce Therapeutics among major losers
Gainers: DBV Technologies (DBVT) +61%, AnPac Bio-Medical Science (ANPC) +16%, Community Health Systems (CYH) +15%, ProPhase Labs (PRPH) +12%, ZIOPHARM Oncology (ZIOP) +10%.Losers: Liquidia Technologies (LQDA) -28%, Jounce Therapeutics (JNCE) -26%, Rexahn Pharmaceuticals (REXN) -16%, Cogent Biosciences (COGT) -11%, Cleveland BioLabs (CBLI) -8%.
Seekingalpha · 11/02 15:55
BioLineRx, Acadia Healthcare leads healthcare gainers; Axovant Gene Therapies, Bellicum Pharmaceuticals among major losers
Gainers: BioLineRx BLRX +63%, Acadia Healthcare ACHC +19%, Tricida (TCDA) +14%, Cleveland BioLabs (CBLI) +12%, Equillium EQ +4%.Losers: Axovant Gene Therapies (AXGT) -39%, Bellicum Pharmaceuticals (BLCM) -38%, OPKO Health (OPK) -20%, Cellect Biotechnology (APOP) -17%, Neovasc (NVCN) -16%.
Seekingalpha · 10/30 14:59
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations – CBLI, PE, CEIX, PNM
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:Cleveland BioLabs, Inc.
ACCESSWIRE · 10/29 14:30
Cytocom, Inc. Issues Shareholder Letter To Stockholders Of Cytocom And BioLabs
  WINTER PARK, Fla., Oct. 21, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced that its Chief Executive Officer, Michael K. Handley, has
Benzinga · 10/21 12:32
Netflix, GSX Techedu leads premarket losers' pack
GSX Techedu (GSX) -24%.Armstrong Flooring (AFI) -22% after Q3 earnings.Iterum Therapeutics (ITRM) -18%.China Index Holdings (CIH) -15%.Code Chain New Continent (CCNC) -14%.Dragon Victory International (LYL) -12%.CRISPR Therapeutics (CRSP) -11% after announcing positive top-line
Seekingalpha · 10/21 12:28
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cleveland BioLabs, Inc. (NASDAQ:CBLI)
BALA CYNWYD, PA / ACCESSWIRE / October 20, 2020 / Law Office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cleveland BioLabs, Inc.
ACCESSWIRE · 10/20 23:51
Mid-Afternoon Market Update: Dow Rises 1%; Aptinyx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 1% to 28,476.42 while the NASDAQ rose 1.06% to 11,600.59. The S&P also rose, gaining 1.15% to 3,466.20.
Benzinga · 10/20 18:34
NNDM, CIH, BCLI and CBLI among midday movers
Gainers: Cleveland BioLabs (CBLI) +66%.9F (JFU) +47%.Molecular Data (MKD) +35%.Natuzzi (NTZ) +30%.Aptinyx (APTX) +26%.VOXX International (VOXX) +23%.Pro-Dex (PDEX) +21%.SunLink Health Systems (SSY) +21%.China Index Holdings (CIH) +14%.Anchiano Therapeutics (ANCN) +11%.Losers: Kaixin Auto
Seekingalpha · 10/20 16:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBLI. Analyze the recent business situations of Cleveland Biolbs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 345.71K
% Owned: 2.66%
Shares Outstanding: 13.02M
TypeInstitutionsShares
Increased
1
6.05K
New
5
32.67K
Decreased
6
109.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Lea Verny
President
Langdon Miller
Chief Executive Officer/Chief Financial Officer/Vice President - Finance
Christopher Zosh
Chief Scientific Officer
Andrei Gudkov
Independent Director
Alexander Andryushechkin
Independent Director
Anna Evdokimova
Independent Director
Ivan Fedyunin
Independent Director
Randy Saluck
Independent Director
Daniil Talyanskiy
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CBLI
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cleveland BioLabs, Inc. stock information, including NASDAQ:CBLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBLI stock methods without spending real money on the virtual paper trading platform.